Core Insights - Aethlon Medical has achieved a key milestone by treating the first patient in the Hemopurifier® safety, feasibility, and dose-finding study for solid tumors not responding to anti-PD-1 antibodies [1] - The company has opened patient enrollment at two clinical sites in Australia for the Hemopurifier cancer trial [1] - Significant reductions in operating expenses have been reported, enhancing operational efficiency [1] Clinical Trials - The Australian oncology trial of the Hemopurifier has seen steady progress, with three patients enrolled so far [2] - One patient successfully underwent a 4-hour Hemopurifier treatment without complications, while two patients were withdrawn due to pre-specified stopping criteria [2][9] - Protocol modifications have been made to improve enrollment speed and reduce screen failures, including changes to patient eligibility criteria [3][4] Regulatory Approvals - The amended protocol for the trial has received approval from Human Research Ethics Committees (HREC) at all three clinical sites [5] - Aethlon is pursuing a similar clinical trial in India, with HREC approval obtained at Medanta Medicity Hospital, awaiting further regulatory approval [6] Operational Efficiency - Strategic cost-cutting measures have been implemented to optimize resources and reduce operational expenses [7] - The company reported a 50% decrease in consolidated operating expenses for the fiscal quarter ended December 31, 2024, amounting to approximately $1.8 million [14] Financial Results - As of December 31, 2024, Aethlon had a cash balance of approximately $4.8 million [13] - The net loss for the fiscal quarter decreased to approximately $1.8 million from approximately $3.5 million in the same quarter of the previous year [18] - Operating expenses decreased significantly due to reductions in payroll, professional fees, and general administrative expenses [14][15][17] Future Outlook - The primary endpoint of the ongoing trials is safety, with a focus on monitoring adverse events and changes in lab tests for Hemopurifier-treated patients [9][10] - The Hemopurifier aims to improve therapeutic response rates to anti-PD-1 antibodies by removing extracellular vesicles (EVs) from the bloodstream [11]

Core Viewpoint - Aethlon Medical, Inc. is set to release its financial results for the fiscal third quarter ending December 31, 2024, on February 12, 2025, at 4:15 p.m. ET [1] Financial Results Announcement - The financial results will be discussed in a conference call on February 12, 2025, at 4:30 p.m. ET, which will include a question and answer session [2] - Interested parties can register for the conference call online, and registered participants will receive their dial-in number upon registration [2] Conference Call Details - For those without internet access, a toll-free number is available for participation: 1-844-836-8741 (domestic) and 1-412-317-5442 (international) [3] - A replay of the call will be available approximately one hour after the call ends and can be accessed through Aethlon Medical's website or by dialing specific numbers for domestic and international callers [4] Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an immunotherapeutic device aimed at treating cancer and life-threatening viral infections [5] - The Hemopurifier has shown promise in human studies for removing life-threatening viruses and harmful exosomes, which may contribute to immune suppression and cancer metastasis [5] - The device has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses not addressed by approved therapies [5]

Core Insights - Aethlon Medical has achieved a significant milestone by treating the first patient with the Hemopurifier in a clinical trial targeting solid tumors that do not respond to anti-PD-1 therapies [1][3] - The trial aims to assess the safety, feasibility, and dosing of the Hemopurifier in patients with stable or progressive disease after anti-PD-1 monotherapy [5] Company Overview - Aethlon Medical, Inc. is a publicly traded medical device company based in San Diego, California, focused on developing therapeutic devices to treat cancer and life-threatening infectious diseases [7] - The Hemopurifier is designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation, potentially improving responses to existing cancer therapies [6][7] Clinical Trial Details - The clinical trial involves approximately 18 patients and will monitor the incidence of adverse events and changes in safety lab tests after treatment with the Hemopurifier [5] - The study will also evaluate the number of Hemopurifier treatments required to decrease extracellular vesicle concentrations and whether this enhances the body's ability to attack tumor cells [5] Treatment Context - Only 30-40% of patients receiving pembrolizumab or nivolumab show lasting clinical responses, highlighting the need for alternative treatment strategies [4] - The Hemopurifier has shown promise in preclinical studies by reducing the number of exosomes in cancer patient plasma, which may help overcome resistance to anti-PD-1 therapies [4][6]

SAN DIEGO, Dec. 20, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided a statement of its investigational medical device with respect to H5N1 avian influenza "Bird Flu."Aethlon has recently received a number of inquiries regarding the potential utility of its Hemopurifier device in the treatment of Bird Flu. These inquiries come on the heels of the reporting of isolat ...

Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise GloballyNovember 14, 2024 8:00 AM EST | Source: Econ Corp Services DBA Investorideas.comVancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 14, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases a snapshot looking at the advancement of treatments for solid tumors as global cancer incidence rates rise ...

Aethlon Medical, Inc. (NASDAQ:AEMD) Q2 2025Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relations, Rx Communications James Frakes - Interim Chief Executive Officer & Chief Financial Officer Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Jeremy Pearlman - Maxim Group Operator Good day, and welcome to the Aethlon Medical Fiscal Second Quarter 2025 Earnings and Corporate Update. [Operator Instructions] Please note t ...

Financial Performance - Total current assets increased to $7,138,083 as of September 30, 2024, up from $6,225,788 as of March 31, 2024, representing a growth of 14.6%[9] - Total liabilities rose to $2,828,222 as of September 30, 2024, compared to $2,479,650 as of March 31, 2024, indicating an increase of 14.1%[10] - The net loss for the three months ended September 30, 2024, was $2,806,973, a decrease from the net loss of $3,034,456 for the same period in 2023, reflecting an improvement of 7.5%[13] - Basic and diluted loss per share for the three months ended September 30, 2024, was $(0.20), compared to $(1.22) for the same period in 2023, showing a significant reduction in loss per share[13] - For the six months ended September 30, 2024, the net loss was $5,378,414, compared to a net loss of $6,316,635 for the same period in 2023, representing a 14.8% improvement in losses year-over-year[17] Cash and Assets - Cash and cash equivalents increased to $6,859,075 as of September 30, 2024, compared to $5,441,978 as of March 31, 2024, marking a rise of 26.0%[9] - The cash and restricted cash at the end of the period on September 30, 2024, was $6,946,581, compared to $10,263,426 at the end of the same period in 2023, reflecting a decrease in available cash[17] - The total stockholders' equity as of September 30, 2024, was $6,019,108, up from $5,766,332 as of March 31, 2024, reflecting an increase of 4.4%[11] - The accumulated deficit as of September 30, 2024, was $(159,945,141), compared to $(154,566,728) as of March 31, 2024, indicating an increase in the deficit[11] Operating Expenses - Total operating expenses for the six months ended September 30, 2024, were $5,521,856, down from $6,583,506 for the same period in 2023, a decrease of 16.2%[13] - Professional fees for the three months ended September 30, 2024, were $570,845, down from $1,133,111 for the same period in 2023, a decrease of 49.6%[13] - Payroll and related expenses for the three months ended September 30, 2024, increased to $1,372,899 from $1,191,426 in 2023, an increase of 15.2%[13] - The company reported total operating expenses of $2,902,119 for the three months ended September 30, 2024, down from $3,175,346 in the same period of 2023, a decrease of 8.61%[13] Research and Development - The company incurred research and development expenses of $261,486 for the three months ended September 30, 2024, compared to $628,447 for the same period in 2023, representing a decrease of approximately 58.4%[47] - For the six months ended September 30, 2024, research and development expenses totaled $702,115, down from $1,687,010 in the same period of 2023, indicating a reduction of about 58.3%[47] Clinical Trials and Product Development - The Hemopurifier has been designated as a "Breakthrough Device" by the FDA for treating advanced or metastatic cancer and life-threatening viral infections, highlighting its potential in critical medical applications[18] - Clinical trials for the Hemopurifier have commenced in Australia and India, focusing on safety, feasibility, and dose-finding in cancer patients, with trials involving approximately 9 to 18 patients in each country[20][22] - The company has established a wholly-owned subsidiary in Australia to conduct oncology-related clinical research and seek regulatory approval for the Hemopurifier[19] - The Hemopurifier has shown potential in removing harmful exosomes and exosomal particles, which may contribute to cancer progression and immune suppression[18] - The company has successfully enrolled the first two patients in its Australian clinical trial for the Hemopurifier, marking a significant milestone in its clinical program[85] Financing Activities - The company raised $5,384,307 from the issuance of common stock during the six months ended September 30, 2024, compared to $1,086,119 in the same period of 2023, indicating a significant increase in financing activities[17] - The company completed a public offering on May 17, 2024, raising gross proceeds of approximately $4.7 million, with net proceeds of about $3.5 million after deducting fees and expenses[55] Management and Governance - The company appointed James B. Frakes as the permanent CEO effective October 3, 2024, while also retaining his role as CFO[84] - In April 2024, the company granted 32,894 RSUs to each of the four eligible non-employee directors, with each RSU priced at $1.52 per share[59] - For the three months ended September 30, 2024, the company accrued $68,250 for board fees and paid out $68,250, compared to $57,000 paid in the same period in 2023[60] Legal and Regulatory Matters - The company is currently not involved in any litigation or pending legal proceedings, reflecting a stable legal environment[82] - The company has received ethics review board approval for its COVID-19 clinical trial at Medanta Medicity Hospital and Maulana Azad Medical College in India[29] Future Outlook - The company expects that existing cash as of September 30, 2024, will not be sufficient to fund operations for at least twelve months from the issuance date of its financial statements[43] - The company is closely monitoring the impact of global events such as inflation and military conflicts on its business operations and financial condition[33]

Exhibit 99.1 Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies Two Australian Sites Open For Patient Enrollment in Hemopurifier® Cancer Trial Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, November 13, 2024 -- Ae ...

Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 AntibodiesTwo Australian Sites Open For Patient Enrollment in Hemopurifier® Cancer TrialConference Call to be Held Today at 4:30 p.m. ETSAN DIEGO, Nov. 13, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening in ...

Industry Overview - The Medical Technology market is projected to reach US$597.00 billion by 2024, with Medical Devices expected to dominate at US$508.00 billion. The market is anticipated to grow at a steady annual rate of 5.29% from 2024 to 2029 [2][20]. Company Highlights: Aethlon Medical, Inc. - Aethlon Medical has enrolled the first patient in its clinical trial for the Hemopurifier®, aimed at treating solid tumors during anti-PD-1 therapy. This milestone was achieved on October 29, 2024, at the Royal Adelaide Hospital in Australia [3][6]. - The Hemopurifier is designed to remove life-threatening viruses and harmful exosomes from biological fluids, potentially improving therapeutic responses to anti-PD-1 therapies like Keytruda® and Opdivo® [4][6]. - Current response rates to anti-PD-1 therapies are approximately 30-40%, and the Hemopurifier aims to enhance these rates by targeting extracellular vesicles (EVs) implicated in cancer spread and therapy resistance [6][7]. Clinical Trial Details - The trial will involve approximately 9 to 18 patients, focusing on safety, feasibility, and dose-finding, with the primary endpoint being the incidence of adverse events and significant changes in safety lab tests [7][8]. - Patients will undergo a two-month run-in period with anti-PD-1 therapy, after which those not responding will receive Hemopurifier treatments [5][7]. Other Notable Developments in Medical Technology - Royal Philips has initiated the THOR IDE clinical trial, studying a combined laser atherectomy and intravascular lithotripsy catheter, which simplifies procedures for treating peripheral artery disease (PAD) [9][12]. - Microbot Medical has completed enrollment for its ACCESS-PVI clinical trial and plans to file for FDA clearance by the end of 2024 [13][14]. - BD (Becton, Dickinson and Company) has also enrolled the first patient in its AGILITY study, assessing a self-expanding vascular covered stent for PAD treatment [17][19].